-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target

Benzinga·10/07/2026 12:46:09
Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and maintains $15 price target.